Acute and late coronary outcomes in 1073 patients with Kawasaki disease with and without intravenous γ-immunoglobulin therapy

Arch Dis Child. 2015 Jun;100(6):542-7. doi: 10.1136/archdischild-2014-306427. Epub 2015 Jan 6.

Abstract

Objective: To explore acute and late coronary outcomes and their risk/modifiers in patients with Kawasaki disease (KD).

Design: Retrospective study.

Setting and patients: 1073 patients with KD identified from a tertiary care medical centre (1980-2012; 8677 patient-years).

Main outcome measures: The acute coronary severities and late outcomes (survival free of coronary aneurysm persistence and ischaemia) were assessed.

Results: Coronary arterial lesions occurred in 40.6% of cases at their acute febrile stages, and persisted beyond 1 month in 196 (18.3%, M/F=138/58) patients: 125 (11.6%) had small aneurysms, 44 (4.1%) had medium aneurysms, and 27 (2.5%) had giant aneurysms. At follow-up (1-46 years), coronary aneurysms persisted in all with giant aneurysms, in 55% of those with medium aneurysms (18% with stenosis), and in 9% of those with small aneurysms. Ischaemia events occurred in 14 patients (M/F=13/1) and caused four deaths. Among the patients with KD with coronary aneurysms, 10-year ischaemia event-free and aneurysm persistence probability was 87.5% and 20.6%, respectively. The only independent risk for aneurysm persistence was the aneurysm severity 1 month after KD onset (χ(2)=80.73, p<10(-3)). Male patients and intravenous γ-immunoglobulin (IVIG) therapy were independent risk factors of initial coronary severity but were not associated with the late coronary outcomes, even in severity stratified subgroups.

Conclusions: The coronary severity 1 month after KD onset is most crucial to the late coronary outcomes. Although IVIG use improves the initial severity of coronary lesions, it does not further modify the long-term fate of coronary aneurysms.

Keywords: Cardiology; Coronary arterial lesions; Kawasaki disease; Myocardial ischemia; Risk factors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Coronary Artery Disease / drug therapy
  • Coronary Artery Disease / etiology*
  • Coronary Vessels / pathology*
  • Female
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use*
  • Male
  • Mucocutaneous Lymph Node Syndrome / complications*
  • Mucocutaneous Lymph Node Syndrome / drug therapy
  • Retrospective Studies
  • Risk Factors
  • Treatment Outcome

Substances

  • Immunoglobulins, Intravenous